Senseonics Holdings Inc (NYSEAMERICAN:SENS) was the target of a significant increase in short interest in August. As of August 31st, there was short interest totalling 14,340,210 shares, an increase of 3.5% from the August 15th total of 13,861,627 shares. Based on an average daily volume of 1,501,759 shares, the short-interest ratio is presently 9.5 days. Currently, 15.9% of the company’s stock are short sold.
A number of hedge funds have recently added to or reduced their stakes in the business. Tibra Equities Europe Ltd bought a new stake in shares of Senseonics during the 1st quarter valued at approximately $546,000. Element Capital Management LLC bought a new stake in shares of Senseonics during the 1st quarter valued at approximately $309,000. Millennium Management LLC grew its holdings in shares of Senseonics by 43.5% during the 1st quarter. Millennium Management LLC now owns 1,387,566 shares of the company’s stock valued at $4,163,000 after purchasing an additional 420,358 shares during the last quarter. Bank of Montreal Can bought a new stake in shares of Senseonics during the 2nd quarter valued at approximately $1,030,000. Finally, Broadview Advisors LLC bought a new stake in shares of Senseonics during the 2nd quarter valued at approximately $2,774,000. 30.66% of the stock is currently owned by hedge funds and other institutional investors.
Senseonics stock traded down $0.09 during midday trading on Friday, hitting $3.86. The company’s stock had a trading volume of 1,356,488 shares, compared to its average volume of 1,481,340. Senseonics has a 1-year low of $2.36 and a 1-year high of $5.29. The company has a current ratio of 2.93, a quick ratio of 2.81 and a debt-to-equity ratio of 0.76.
Senseonics (NYSEAMERICAN:SENS) last issued its quarterly earnings data on Wednesday, August 8th. The company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.09). Senseonics had a negative return on equity of 406.72% and a negative net margin of 828.76%. The business had revenue of $3.62 million during the quarter, compared to analyst estimates of $3.87 million. During the same quarter last year, the firm earned ($0.12) EPS. Senseonics’s revenue for the quarter was up 345.1% compared to the same quarter last year. Analysts predict that Senseonics will post -0.54 EPS for the current fiscal year.
A number of research firms recently weighed in on SENS. Raymond James raised their target price on shares of Senseonics from $4.00 to $6.00 and gave the company an “outperform” rating in a research report on Friday, June 22nd. Craig Hallum assumed coverage on shares of Senseonics in a research note on Monday, June 11th. They issued a “buy” rating and a $7.00 price target for the company. BTIG Research reiterated a “buy” rating and issued a $6.00 price target on shares of Senseonics in a research note on Thursday, August 9th. Finally, Dougherty & Co assumed coverage on shares of Senseonics in a research note on Friday, August 24th. They issued a “buy” rating and a $6.00 price target for the company. Six analysts have rated the stock with a buy rating, The company has an average rating of “Buy” and a consensus target price of $6.00.
Senseonics Company Profile
Senseonics Holdings, Inc, a medical technology company, designs, develops, and commercializes continuous glucose monitoring (CGM) systems for people with diabetes primarily in Europe. Its products include Eversense and Eversense XL, which are implantable CGM systems that is designed to continually and accurately measure glucose levels in people with diabetes for a period of up to 90 and 180 days.
See Also: S&P 500 Index
Receive News & Ratings for Senseonics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senseonics and related companies with MarketBeat.com's FREE daily email newsletter.